Advertisement

Topics

AbCellera Biologics Inc. Company Profile

04:28 EST 12th December 2018 | BioPortfolio

AbCellera is a privately held company that engages in partnerships to discover and develop next-generation therapeutic antibodies. AbCellera’s single-cell platform integrates end-to-end capabilities for therapeutic antibody discovery through a combination of technologies including proprietary immunizations, microfluidics, high-throughput imaging, genomics, computation, and laboratory automation. Ultra-deep screening of single B cells allows unprecedented access to natural immune responses, enabling rapid isolation of large and diverse panels of high-quality lead antibodies from any species, including humans.


News Articles [495 Associated News Articles listed on BioPortfolio]

AbCellera Collaborates With Denali Therapeutics To Treat Neurodegenerative Diseases

NewsThe collaboration uses AbCellera’s high-throughput single-cell screening capabilities to find new antibodies against a target identified by Denali linked to neurodegenerative disorders.

AbCellera and Denali collaborate to discover new antibodies to fight neurodegenerative diseases

AbCellera Biologics Inc. today announced the successful completion of the first phase of its collaboration with Denali Therapeutics Inc.

Denali and AbCellera to collaborate on treating neurodegenerative disease

US-based biopharmaceutical company Denali Therapeutics has formed an alliance with Canadian therapeutic discovery firm AbCellera Biologics to identify new antibodies...Read More... The post Denali and...

AbCellera secures $10mm Series A investment

AbCellera Biologics Inc. (antibody discovery) raised $10mm in its Series A financing round led by DCVC Bio (adds 2 board seats).

M&As this week: WIRB-Copernicus, AbCellera Biologics, Apricus Biosciences

WIRB-Copernicus Group has completed the acquisition of KMR Group and Metrics Champion Consortium (MCC) for an undisclosed sum. The acquired...Read More... The post M&As this week: WIRB-Copernicus...

AbCellera, Autolus partner on antibody discovery project

Under the partnership, AbCellera is applying its microfluidic single-cell screening platform to find novel antibodies which can be used for the development of new Chimeric Antigen Receptor (CAR) The ...

AbCellera Acquires Lineage Biosciences

AbCellera expands its antibody discovery capabilities by capturing foundational repertoire sequencing technology from immune profiling start-up. AbCellera Biologics Inc...

AbCellera Announces Collaboration with Denali Therapeutics to Discover New Antibodies to Treat ...

Collaboration uses AbCellera’s high-throughput single-cell screening capabilities to find new antibodies against a target identified by Denali linked to neurodegenerative disorders ...

Drugs and Medications [3 Associated Drugs and Medications listed on BioPortfolio]

Standardized cat pelt [Jubilant HollisterStier LLC]

ALLERGENIC EXTRACT STANDARDIZED CAT PELT AP ACETONE PRECIPITATED

Standardized cat hair [Jubilant HollisterStier LLC]

ALLERGENIC EXTRACT STANDARDIZED CAT HAIR AP Acetone Precipitated

Cinryze [ViroPharma Biologics]

These highlights do not include all the information needed to use CINRYZE™ safely and effectively. See full prescribing information for CINRYZE.CINRYZE™ (C1 Esterase Inhibitor [Human]) For Intrave...

PubMed Articles [98 Associated PubMed Articles listed on BioPortfolio]

Considerations for implementing an informatics system to support biologics drug discovery.

A comprehensive, well-functioning and scientifically aware informatics environment is of the utmost importance in supporting effective drug discovery programs. However, implementing such a system can,...

Advanced formulations for Intranasal Delivery of Biologics.

The global biologics market has been ever increasing over the last decades and is predicted to top Euro 350 by 2020. Facing this scenario, the parenteral route of biologics administration as hitherto ...

Persistence of treatment with biologics for patients with psoriasis: a real-world analysis of 16,545 biologic-naïve patients from the French national health insurance database (SNIIRAM).

Long-term clinical effectiveness of biologics in psoriasis is needed.

Biologics Monitoring: Incongruity between Recommendations and Clinician Monitoring Trends.

Biologics are a commonly used treatment for moderate to severe psoriasis. Monitoring laboratory test overuse provide little definitive benefit to patients.

Dose Increase beyond Labelled Dose of Biologics Is Associated With Incremental Pharmacy Costs: Results from a Real-World Study In the UK.

Evidence regarding dosing patterns of biologics among moderate to severe psoriasis patients and impact on costs in the United Kingdom (UK) is limited.

Clinical Trials [83 Associated Clinical Trials listed on BioPortfolio]

A Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA)

The purpose of this study is to compare the efficacy of Biologics + Methotrexate with Biologics + Tacrolimus measured by the disease activity score 28 (DAS28) erythrocyte sedimentation rat...

Ustekinumab Safety and Surveillance Program Using the Ingenix NHI Database

The patients included in this observational study will be drawn from a research database containing claims and enrollment data for members of a large, geographically diverse US health plan...

Golimumab Safety and Surveillance Program Using the Ingenix NHI Database

The participants included in this observational study will be drawn from a research database containing claims and enrollment data for members of a large, geographically diverse US health ...

Real World Effectiveness of Ustekinumab in Induction and Maintenance Therapy for Crohn´s Disease

"RUN-CD" is an investigator initiated "Non interventional Trial" on biologics in Crohn´s Disease (CD) patients in Germany with a prospective documentation of effectiveness in induction an...

Tight Control Dose Reductions of Biologics in Psoriasis Patients With Low Disease Activity

Rationale/hypothesis: Moderate-to-severe psoriasis can be treated with biologics. Objective To investigate whether the dose of biologics can be reduced in patients with psoriasis with sta...

Companies [270 Associated Companies listed on BioPortfolio]

AbCellera Biologics, Inc.

AbCellera is a privately held company that develops next-generation monoclonal antibody therapies and provides enabling technologies to biotechnology and pharmaceutical partners. ...

AbCellera Biologics Inc.

AbCellera is a privately held company that engages in partnerships to discover and develop next-generation therapeutic antibodies. AbCellera’s single-cell platform integrates...

ABEC and WuXi Biologics

WuXi Biologics, a Hong Kong-listed company, is the only open-access biologics technology platform in the world offering end-to-end solutions to empower organizations to discover d...

Burst Biologics

Burst Biologics is a rapidly growing Biotechnology Company and federally registered tissue bank located in Boise, Idaho. Burst Biologics is a developer of effective tissue process...

MSD Biologics (UK) Limited

Avecia Biologics was acquired in February 2010 by MSD, the UK subsidiary of Merck & Co Inc, the world’s second largest pharmaceutical company. MSD Billingham is one of the world's leading contract ...

More Information about "AbCellera Biologics Inc." on BioPortfolio

We have published hundreds of AbCellera Biologics Inc. news stories on BioPortfolio along with dozens of AbCellera Biologics Inc. Clinical Trials and PubMed Articles about AbCellera Biologics Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of AbCellera Biologics Inc. Companies in our database. You can also find out about relevant AbCellera Biologics Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Alliances, mergers acquisitions and partnerships
BioPortfolio's alliances, mergers acquisitions and partnerships channel provides the latest news and corporate information on the global bio-pharmaceutical industry.

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...


Corporate Database Quicklinks



Searches Linking to this Company Record